{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:49:18Z","timestamp":1785887358577,"version":"3.56.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,2]],"date-time":"2027-03-02T00:00:00Z","timestamp":1803945600000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijgc.2025.102783","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:29:46Z","timestamp":1772443786000},"page":"102783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates and evolving care paradigms for pre-menopausal patients with endometrial cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Ray Abou","family":"Nakad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2025.102783_bib1","unstructured":"Cancer stat facts: uterine cancer. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Accessed October 6, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html."},{"key":"10.1016\/j.ijgc.2025.102783_bib2","unstructured":"Obesity and cancer. National Cancer Institute. Accessed October 6, 2025. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/obesity\/obesity-fact-sheet."},{"key":"10.1016\/j.ijgc.2025.102783_bib3","unstructured":"Overweight & obesity statistics. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed October 6, 2025. https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/overweight-obesity."},{"issue":"17","key":"10.1016\/j.ijgc.2025.102783_bib4","first-page":"1","article-title":"Births: final data for 2020","volume":"70","author":"Osterman","year":"2021","journal-title":"Natl Vital Stat Rep."},{"issue":"6","key":"10.1016\/j.ijgc.2025.102783_bib5","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/humrep\/den106","article-title":"The impact of a decline in fecundity and of pregnancy postponement on final number of children and demand for assisted reproduction technology","volume":"23","author":"Leridon","year":"2008","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ijgc.2025.102783_bib6","unstructured":"NCCN clinical practice guidelines in oncology: uterine neoplasms. version 3.2025. National Comprehensive Cancer Network. Accessed October 6, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1473."},{"issue":"1","key":"10.1016\/j.ijgc.2025.102783_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/hropen\/hoac057","article-title":"ESGO\/ESHRE\/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"2023","author":"Rodolakis","year":"2023","journal-title":"Hum Reprod Open"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102783_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/IGC.0000000000001164","article-title":"Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis","volume":"28","author":"Fan","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102783_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2012.08.011","article-title":"Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis","volume":"207","author":"Gallos","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102783_bib10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","article-title":"Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review","volume":"125","author":"Gunderson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102783_bib11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/IGC.0000000000000723","article-title":"Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis","volume":"26","author":"Qin","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102783_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2004.06.045","article-title":"Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review","volume":"95","author":"Ramirez","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102783_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/jnci\/djae023","article-title":"Levonorgestrel-releasing intrauterine device therapy vs oral progestin treatment for reproductive-aged patients with endometrial intraepithelial neoplasia: a systematic review and meta-analysis","volume":"116","author":"Suzuki","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijgc.2025.102783_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2025.06.015","article-title":"Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: results of a specialized oncofertility program","volume":"199","author":"Dzyubak","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102783_bib15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ijgc-00009577-200509000-00041","article-title":"Reproductive preservation for treatment of stage IA endometrial cancer in a young woman: hysteroscopic resection","volume":"15","author":"Mazzon","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102783_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jmig.2018.07.001","article-title":"Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retrospective study","volume":"26","author":"Giampaolino","year":"2019","journal-title":"J Minim Invas Gynecol"},{"key":"10.1016\/j.ijgc.2025.102783_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2023.11.006","article-title":"Molecular subtyping in endometrial cancer: a promising strategy to guide fertility preservation","volume":"179","author":"Dagher","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102783_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2021.01.029","article-title":"Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: results of a randomized clinical trial","volume":"161","author":"Janda","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102783_bib19","series-title":"Presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer (SGO)","article-title":"Metformin with the levonorgestrel-releasing intrauterine device for the treatment of endometrial intraepithelial neoplasia and endometrial cancer in non-surgical patients","author":"Haag","year":"2025"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102783_bib20","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1136\/ijgc-2022-003882","article-title":"Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia","volume":"32","author":"Chen","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.102783_bib21","unstructured":"Levonorgestrel-releasing intrauterine system with or without everolimus in treating patients with atypical hyperplasia or stage IA Grade 1 endometrial cancer (LEVER). ClinicalTrials.gov. Accessed October 6, 2025. https:\/\/clinicaltrials.gov\/study\/NCT02397083."},{"issue":"4","key":"10.1016\/j.ijgc.2025.102783_bib22","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.3802\/jgo.2021.32.e57","article-title":"Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment","volume":"32","author":"Zhou","year":"2021","journal-title":"J Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102783_bib23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijgc.2025.102783_bib24","unstructured":"Concurrent laparoscopic hysterectomy and weight loss surgery in obese patients with endometrial carcinoma or endometrial intraepithelial neoplasia. ClinicalTrials.gov. Accessed October 6, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT04839614."},{"issue":"7","key":"10.1016\/j.ijgc.2025.102783_bib25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1471-0528.16108","article-title":"Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial","volume":"127","author":"Yang","year":"2020","journal-title":"BJOG"},{"issue":"7447","key":"10.1016\/j.ijgc.2025.102783_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102783_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2025.102783_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ygyno.2023.05.059","article-title":"Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma","volume":"174","author":"Rios-Doria","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102783_bib29","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.102783_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2022.10.017","article-title":"Sentinel lymph node mapping in patients with endometrial hyperplasia: a practice to preserve or abandon?","volume":"168","author":"Mueller","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102783_bib31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/ijgc-2023-005194","article-title":"Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation","volume":"34","author":"Manning-Geist","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.102783_bib32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2024.04.013","article-title":"Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment","volume":"186","author":"Peng","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102783_bib33","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/1471-0528.14491","article-title":"Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series","volume":"124","author":"Zakhour","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.ijgc.2025.102783_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejogrb.2024.09.006","article-title":"Fertility-sparing treatment in MSI-H\/MMRd endometrial carcinoma or atypical endometrial hyperplasia: a systematic review and meta-analysis","volume":"302","author":"Zhang","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102783_bib35","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e35","article-title":"A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)","volume":"36","author":"Lee","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102783_bib36","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3802\/jgo.2025.36.e59","article-title":"Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome","volume":"36","author":"Yang","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102783_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/curroncol32060317","article-title":"Molecular classification guides fertility-sparing treatment for endometrial cancer and atypical hyperplasia patients","volume":"32","author":"Wang","year":"2025","journal-title":"Curr Oncol"},{"issue":"29","key":"10.1016\/j.ijgc.2025.102783_bib38","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer risks for PMS2-associated Lynch syndrome","volume":"36","author":"Ten Broeke","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijgc.2025.102783_bib39","unstructured":"Genetic\/familial high-risk assessment: breast, ovarian, pancreatic, and prostate. version 1.2026. National Comprehensive Cancer Network. Accessed October 6, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1545."},{"issue":"21","key":"10.1016\/j.ijgc.2025.102783_bib40","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial cancer","volume":"383","author":"Lu","year":"2020","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.ijgc.2025.102783_bib41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/djad016","article-title":"Comprehensive analysis of germline drivers in endometrial cancer","volume":"115","author":"Gordhandas","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijgc.2025.102783_bib42","article-title":"Clinical and fertility outcomes in Lynch syndrome patients with endometrial carcinoma or endometrial intraepthelial neoplasia treated with fertility-sparing management","volume":"59","author":"Reid","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.ijgc.2025.102783_bib43","article-title":"Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia in patients with Lynch syndrome: molecular diagnosis after immunohistochemistry of MMR proteins","volume":"9","author":"Catena","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102783_bib44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1525-1438.2007.00996.x","article-title":"The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology","volume":"18","author":"Chi","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102783_bib45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2020.03.025","article-title":"Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma","volume":"157","author":"Mueller","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102783_bib46","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ejso.2016.03.009","article-title":"Accuracy of preoperative endometrial sampling diagnosis for predicting the final pathology grading in uterine endometrioid carcinoma","volume":"42","author":"Batista","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102783_bib47","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1148\/rg.220070","article-title":"Update on MRI in evaluation and treatment of endometrial cancer","volume":"42","author":"Maheshwari","year":"2022","journal-title":"RadioGraphics"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102783_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2023.04.027","article-title":"Fertility-sparing hormonal treatment in patients with stage I endometrial cancer of grade 2 without myometrial invasion and grade 1-2 with superficial myometrial invasion: gynecologic Oncology Research Investigators collaboration study (GORILLA-2001)","volume":"174","author":"Lee","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102783_bib49","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.3802\/jgo.2020.31.e74","article-title":"Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-group (GCIG) study","volume":"31","author":"Falcone","year":"2020","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102783_bib50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses\u2019 Health Study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102783_bib51","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/GME.0000000000000692","article-title":"Bone loss after oophorectomy among high-risk women: an NRG oncology\/Gynecologic Oncology Group study","volume":"23","author":"Hibler","year":"2016","journal-title":"Menopause"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102783_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8420","article-title":"Changes in bone mineral density after prophylactic bilateral salpingo-oophorectomy in carriers of a BRCA mutation","volume":"2","author":"Kotsopoulos","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102783_bib53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/AOG.0000000000002142","article-title":"Risk of subsequent ovarian cancer after ovarian conservation in young women with stage I endometrioid endometrial cancer","volume":"130","author":"Matsuo","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102783_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jogoh.2024.102722","article-title":"Quality of information and decision regrets during fertility-sparing management for atypical hyperplasia and endometrial cancer in a prospective cohort study","volume":"53","author":"Grenot","year":"2024","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102783_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40271-020-00443-6","article-title":"Shared decision making in surgery: a meta-analysis of existing literature","volume":"13","author":"Niburski","year":"2020","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102783_bib56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11764-016-0563-2","article-title":"Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients","volume":"11","author":"Chan","year":"2017","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.ijgc.2025.102783_bib57","unstructured":"PD-1 inhibitor combined with progesterone treatment in FST for patients with MMRd endometrial cancer. ClinicalTrials.gov. Accessed October 6, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06549855."},{"key":"10.1016\/j.ijgc.2025.102783_bib58","unstructured":"Peking University Third Hospital. Effects of GLP-1RAs on reproductive outcomes in PCOS and obesity. ClinicalTrials.gov. Accessed October 6, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06775093."},{"issue":"5","key":"10.1016\/j.ijgc.2025.102783_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101805","article-title":"Multi-center, international endometrial cancer consortium highlights","volume":"35","author":"De Vitis","year":"2025","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2501905X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2501905X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:13:38Z","timestamp":1785885218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2501905X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1048891X2501905X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102783","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates and evolving care paradigms for pre-menopausal patients with endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102783"}}